October 12, 2016 10:11 AM EDTUpdated October 13, 11:50 AM

Leerink analyst adjusts nusinersen peak to $2.5B; Daiichi Sankyo signs up to work with Dana-Farber team

Shehla Shakoor

Managing Director

Count Geoffrey Porges in the mix of analysts cheering Ionis $IONS and Biogen $BIIB forward on fresh evidence of the efficacy of nusinersen for spinal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Leerink analyst adjusts nusinersen peak to $2.5B; Daiichi Sankyo signs up to work with Dana-Farber team

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Are programs with compounded GLP-1s safe for your population?

Leerink an­a­lyst ad­justs nusin­ersen peak to $2.5B; Dai­ichi Sankyo signs up to work with Dana-Far­ber team

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Leerink analyst adjusts nusinersen peak to $2.5B; Daiichi Sankyo signs up to work with Dana-Farber team

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Are programs with compounded GLP-1s safe for your population?